M. Santoro

发表

The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing

F. Ceccherini‐Silberstein, G. Ippolito, M. Capobianchi, 2013, PloS one.

Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine

V. Calvez, F. Ceccherini‐Silberstein, B. Masquelier, 2011, ChemMedChem.

Marked decrease in acquired resistance to antiretrovirals in latest years in Italy.

S. Lo Caputo, S. Di Giambenedetto, C. Balotta, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2020, The Journal of antimicrobial chemotherapy.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, The Journal of antimicrobial chemotherapy.

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

V. Colizzi, C. Perno, S. Billong, 2020, Antimicrobial Resistance & Infection Control.

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol

A. Wiyeh, F. Ceccherini‐Silberstein, V. Colizzi, 2020, Systematic Reviews.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2021, PloS one.

Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches.

F. Ceccherini‐Silberstein, D. Santoni, C. Perno, 2022, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Giannetti, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of “test and treat”

V. Colizzi, C. Perno, S. Billong, 2019, AIDS Research and Therapy.

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.

F. Ceccherini‐Silberstein, A. Giannetti, A. Antinori, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2008, The Journal of infectious diseases.

Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon

C. Perno, V. Colizzi, C. Perno, 2011, Archives of Virology.

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry

A. d’Arminio Monforte, M. Zazzi, D. Francisci, 2020, Open forum infectious diseases.

Is the rate of virological failure to cART continuing to decline in recent calendar years?

A. d’Arminio Monforte, A. Antinori, A. Cingolani, 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HIV-1 non-B subtypes in Italy: a growing trend.

M. Ciccozzi, M. Ciotti, M. Giovanetti, 2012, The new microbiologica.

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

A. Wensing, H. Günthard, P. Reiss, 2016, The Journal of antimicrobial chemotherapy.

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy

R. Shafer, R. Paredes, J. Montaner, 2014, AIDS.

A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART

V. Calvez, F. Ceccherini‐Silberstein, A. Antinori, 2014, PloS one.

Use of novel antiretroviral agents in rescue regimens: A case of early virological failure to raltegravir

F. Ceccherini‐Silberstein, P. Narciso, L. Pucillo, 2010, Scandinavian journal of infectious diseases.

Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease.

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2021, The Journal of antimicrobial chemotherapy.

Dynamics of NRTI resistance mutations during therapy interruption.

Thomas Lengauer, F. Ceccherini‐Silberstein, P. Narciso, 2009, AIDS research and human retroviruses.

HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2020, PloS one.

The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review

C. Isonne, V. Baccolini, M. Santoro, 2021, Reviews in medical virology.

Archiving of mutations in HIV‐1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP‐READY study

V. Colizzi, C. Perno, M. Santoro, 2021, HIV medicine.

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor

M. Zazzi, M. Colafigli, A. De Luca, 2018, The Journal of antimicrobial chemotherapy.

Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy

F. Ceccherini‐Silberstein, E. Nicastri, A. Antinori, 2015, PloS one.

Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study)

V. Colizzi, C. Perno, N. Kamgaing, 2019, BMC Pediatrics.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.

M. Moroni, G. Filice, R. Maserati, 2008, AIDS patient care and STDs.

Circulation of HIV-1 CRF02_AG among MSM Population in Central Italy: A Molecular Epidemiology-Based Study

M. Ciccozzi, A. Lo Presti, E. Cella, 2013, BioMed research international.

What Are the Effects of Vitamin A Oral Supplementation in the Prevention and Management of Viral Infections? A Systematic Review of Randomized Clinical Trials

C. Isonne, V. Baccolini, M. Santoro, 2022, Nutrients.

HIV MDR is still a relevant issue despite its dramatic drop over the years.

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2020, The Journal of antimicrobial chemotherapy.

Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.

F. Ceccherini‐Silberstein, A. Giannetti, A. Antinori, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells

R. Shafer, C. Walworth, M. Santoro, 2022, Clinical microbiology reviews.

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2022, PLOS Global Public Health.

High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians.

M. Andreoni, V. Colizzi, C. Perno, 2016, Current HIV research.

Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach

F. Ceccherini‐Silberstein, E. Tramontano, S. Alcaro, 2022, Molecules.

Alarming rates of virological failure and HIV‐1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY‐study in Cameroon

F. Ceccherini‐Silberstein, C. Perno, V. Colizzi, 2021, HIV medicine.

HIV-1 Genetic Variability and Clinical Implications

C. Perno, M. Santoro, 2013, ISRN microbiology.

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

F. Ceccherini‐Silberstein, Y. Assaraf, S. Alcaro, 2020, Drug Resistance Updates.

Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database.

A. Giacomelli, A. Castagna, A. Callegaro, 2020, International journal of antimicrobial agents.

Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart

F. Ceccherini‐Silberstein, P. Narciso, E. Nicastri, 2013, Antiviral therapy.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

B. Berkhout, H. Fleury, M. Andreoni, 2015, The Journal of infection.

Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy.

A. Tatem, M. Salemi, M. Ciccozzi, 2011, AIDS research and human retroviruses.

Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

L. Milanesi, F. Ceccherini‐Silberstein, E. Teti, 2021, Viruses.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Huldrych F. Günthard, Tulio de Oliveira, Lynn Morris, 2016 .

Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon

V. Colizzi, P. Ndumbe, C. Perno, 2011, The Pediatric infectious disease journal.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration

Huldrych F. Günthard, Dominique Goedhals, Susan P. Holmes, 2017, EBioMedicine.

Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients

F. Ceccherini‐Silberstein, R. Maserati, P. Narciso, 2009, Infection.

Characterization of drug resistance mutations in naïve and ART‐treated patients infected with HIV‐1 in Yaounde, Cameroon

M. Andreoni, V. Colizzi, J. Torimiro, 2012, Journal of medical virology.

Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe.

F. Ceccherini‐Silberstein, C. Charpentier, C. Perno, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients.

A. Antinori, M. Andreoni, G. Marchetti, 2019, The new microbiologica.

Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV.

Domenico Di Carlo, D. Francisci, F. Maggiolo, 2022, International journal of antimicrobial agents.

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

Domenico Di Carlo, F. Ceccherini‐Silberstein, R. Bellagamba, 2016, The Journal of antimicrobial chemotherapy.

High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations

F. Ceccherini‐Silberstein, F. Gago, A. Antinori, 2005, Journal of Virology.

HIV infection and kidney disease : literature review

M. Santoro, M. Scarpino, G. Pellicano, 2015 .

Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors

Valentina Svicher, Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, 2005, Antimicrobial Agents and Chemotherapy.

Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon

V. Colizzi, C. Fokunang, C. Perno, 2020, PloS one.

Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice

F. Ceccherini‐Silberstein, A. Antinori, M. Zazzi, 2019, Virus Genes.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV‐1 reverse transcriptase (M184L and M184T)

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, Chemical biology & drug design.

Improving the Prediction of Virological Response to Tipranavir: The Development and Validation of a Tipranavir-Weighted Mutation Score

J. Schapiro, C. Boucher, C. Perno, 2010, Antiviral therapy.

Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile

F. Ceccherini‐Silberstein, S. Alcaro, G. Costa, 2022, Microbiology spectrum.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2012, AIDS research and human retroviruses.

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2018, Scientific Reports.

Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains

Francesco Montella, Claudia Alteri, Vanni Borghi, 2017, Journal of Clinical Microbiology.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, BMC Public Health.

Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children

F. Ceccherini‐Silberstein, V. Colizzi, C. Fokunang, 2018, Medicine.

Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2022, Viruses.

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2022, Microbiology spectrum.

High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2021, Diagnostic microbiology and infectious disease.

Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2021, The Journal of antimicrobial chemotherapy.

HIV-1 Drug Resistance and Genetic Diversity among Vertically Infected Cameroonian Children and Adolescents

V. Colizzi, F. Njiokou, C. Perno, 2020 .

Programmatic Challenges in Implementing PMTCT Option B+ and Pediatric HIV Care: Baseline Assessment from “Save the Families for Africa” in Malawi

C. Perno, M. Santoro, J. Fokam, 2019 .

Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV.

L. Calza, M. Zazzi, C. Mussini, 2021, International journal of antimicrobial agents.

Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells

R. Shafer, C. Walworth, M. Santoro, 2022, Clinical microbiology reviews.

Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon

V. Colizzi, C. Fokunang, C. Perno, 2020, AIDS Research and Therapy.

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

F. Ceccherini‐Silberstein, V. Colizzi, C. Fokunang, 2019, BMC Infectious Diseases.

HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design.

F. Ceccherini‐Silberstein, V. Colizzi, J. Eberle, 2016, Current HIV research.

Evaluation of archived drug resistance mutations in HIV‐1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID‐19 pandemic

F. Ceccherini‐Silberstein, Y. Boum, V. Colizzi, 2023, HIV medicine.

Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2015, Journal of Clinical Microbiology.

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens

F. Ceccherini‐Silberstein, P. Narciso, K. Van Laethem, 2010, Journal of acquired immune deficiency syndromes.

Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.

F. Ceccherini‐Silberstein, E. Nicastri, A. Antinori, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V - The LAMRES Study.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2022, Journal of global antimicrobial resistance.

Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy

M. Andreoni, C. Perno, A. Bertoli, 2016, AIDS.

Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.

F. Ceccherini‐Silberstein, O. Turriziani, M. Andreoni, 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors

Thomas Lengauer, Stefano Alcaro, Jan Balzarini, 2007, Journal of Virology.

Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2022, Scientific Reports.

Evaluation of C-terminal p7 (NC)-p6 Gag genetic variants among HIV-1 non-B subtypes in a subset of Cameroonian patients

F. Ceccherini‐Silberstein, M. Santoro, A. Ndjolo, 2021 .

Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors

Thomas Lengauer, A. d’Arminio Monforte, F. Ceccherini‐Silberstein, 2006, Journal of Virology.

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2022, The Journal of antimicrobial chemotherapy.

Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy.

C. Perno, M. Ciccozzi, G. Rezza, 2009, AIDS research and human retroviruses.

Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy

F. Ceccherini‐Silberstein, O. Turriziani, A. Antinori, 2019, Sexually Transmitted Infections.

Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study

F. Ceccherini‐Silberstein, L. Galli, C. Perno, 2021, Viruses.

The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2016, Journal of global antimicrobial resistance.

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.

F. Ceccherini‐Silberstein, A. Antinori, C. Perno, 2022, Journal of Global Antimicrobial Resistance.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, BMC Medicine.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

F. Ceccherini‐Silberstein, E. Nicastri, C. Perno, 2015, The Journal of antimicrobial chemotherapy.

Population Dynamics of HIV-1 Subtype B in a Cohort of Men-Having-Sex-With-Men in Rome, Italy

M. Ciccozzi, A. Lo Presti, G. Zehender, 2010, Journal of acquired immune deficiency syndromes.

The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries.

Tulio de Oliveira, Maureen M Goodenow, Marco Salemi, 2008, AIDS research and human retroviruses.

HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Crosssectional Design

F. Ceccherini‐Silberstein, V. Colizzi, J. Eberle, 2017 .

Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2019, Antiviral therapy.

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.

A. Antinori, F. Incardona, M. Zazzi, 2020, Journal of global antimicrobial resistance.

Clinical relevance of genotypic resistance testing today.

C. Perno, M. Santoro, 2016, The new microbiologica.

The future of long-acting cabotegravir plus rilpivirine therapy: Deeds and misconceptions.

M. Zazzi, S. Rusconi, N. Gianotti, 2022, International journal of antimicrobial agents.

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.

A. d’Arminio Monforte, R. Bruno, A. Lazzarin, 2015, The new microbiologica.

Interpretation of Genotypic HIV-1 Resistance to Darunavir and Virological Response: Validation of Available Systems and of a New Score

F. Baldanti, R. Maserati, P. Narciso, 2011, Antiviral therapy.

Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14

A. Mariano, F. Ceccherini‐Silberstein, V. Vullo, 2017, The Journal of antimicrobial chemotherapy.

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Antinori, 2020, Viruses.

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.

F. Ceccherini‐Silberstein, S. Aquaro, C. Perno, 2020, The Journal of antimicrobial chemotherapy.

Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice

Domenico Di Carlo, A. Antinori, M. Colafigli, 2017, Antiviral therapy.

The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature.

V. Calvez, F. Ceccherini‐Silberstein, C. Perno, 2014, The Journal of infection.

Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.

F. Ceccherini‐Silberstein, M. Ciccozzi, G. Rezza, 2008, AIDS research and human retroviruses.

Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2006, The new microbiologica.

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.

F. Ceccherini‐Silberstein, P. Narciso, M. Capobianchi, 2011, The Journal of antimicrobial chemotherapy.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

F. Ceccherini‐Silberstein, P. Narciso, C. Perno, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The lowest X 4 Geno 2 Pheno false-positive rate is associated with greater CD 4 depletion in HIV-1 infected patients

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2012 .

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Moxifloxacin‐based strategies for first‐line treatment of Helicobacter pylori infection

A. Gasbarrini, V. Ojetti, G. Gasbarrini, 2005, Alimentary pharmacology & therapeutics.

Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens

F. Ceccherini‐Silberstein, V. Colizzi, C. Fokunang, 2023, Viruses.

In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.

M. Zazzi, A. Castagna, F. Maggiolo, 2020, The Journal of antimicrobial chemotherapy.

Factors associated with low-level viremia in people living with HIV in the Italian ARCA cohort: a case-control study.

S. Paolucci, A. Castagna, F. Maggiolo, 2023, AIDS research and human retroviruses.

Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2010, Journal of acquired immune deficiency syndromes.

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2018, Scientific Reports.

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2023, The Journal of antimicrobial chemotherapy.

Virological response and resistance profile in highly treatment‐experienced HIV‐1‐infected patients switching to dolutegravir plus boosted darunavir in clinical practice

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2021, HIV medicine.

Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen.

F. Ceccherini‐Silberstein, A. Lazzarin, L. Galli, 2023, International journal of antimicrobial agents.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Domenico Di Carlo, P. A. Bester, R. Shafer, 2022 .

LERONLIMAB (PRO 140) ACTIVITY AGAINST 4-CLASS DRUG RESISTANT HIV-1 FROM HEAVILY TREATMENT EXPERIENCED SUBJECTS.

M. Zazzi, D. Francisci, L. Galli, 2022, Pharmacological Research.

Pillars of long-term antiretroviral therapy success.

A. Antinori, M. Zazzi, C. Mussini, 2023, Pharmacological research.

Genetic diversity of HIV type 1 in Montenegro.

Marco Ciotti, Aleksandra Marjanovic, Claudia Alteri, 2011, AIDS research and human retroviruses.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

Domenico Di Carlo, F. Ceccherini‐Silberstein, M. Andreoni, 2015, The Journal of antimicrobial chemotherapy.

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon

V. Colizzi, P. Ndumbe, C. Perno, 2011, The Pediatric infectious disease journal.

EVALUATION OF DRUG RESISTANCE EMERGENCE IN HIV-1 INFECTED PATIENTS FAILING A FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY CONTAINING NNRTIS WITH OR WITHOUT THYMIDINE ANALOGUES

P. Narciso, A. Antinori, M. Zazzi, 2009 .

Inflammatory profile of vertically HIV-1 infected adolescents receiving ART in Cameroon: a contribution toward optimal pediatric HIV control strategies

F. Ceccherini‐Silberstein, C. Montesano, V. Colizzi, 2023, Frontiers in immunology.

Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa

F. Ceccherini‐Silberstein, V. Colizzi, M. Santoro, 2024, Journal of virus eradication.

Characterisation of HIV-1 reservoirs in paediatric populations: protocol for a systematic review and meta-analysis

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2023, BMJ Open.

Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens

F. Ceccherini‐Silberstein, V. Colizzi, C. Perno, 2023, Viruses.